

The Elizabeth H. and James S. McDonnell III


GENOME INSTITUTE

at Washington University

Genomic data visualization and interpretation

Malachi Griffith, Obi Griffith, Zachary Skidmore Evomics, Workshop on Genomics Jan 11, 2019 Český Krumlov, Czech Republic

Introductions to course instructors







Malachi Griffith, PhD Assistant Professor of Medicine Assistant Professor of Genetics Assistant Director, MGI

Obi Griffith, PhD Assistant Professor of Medicine Assistant Professor of Genetics Assistant Director, MGI


Zachary Skidmore, MSc Staff Scientist, MGI

GenVisR creator

McDonnell Genome Institute, Washington University School of Medicine



The McDonnell Genome Institute has pursued the field of genomics since inception: >1000 whole genomes, >5000 exomes, >1000 transcriptomes for dozens of tumor types



MGI - 1000+ tumor whole genomes, many more exomes, X10 & NovaSeq will accelerate this!

- Human Genome Project
- First to sequence and analyze a tumor whole genome sequence (Ley et al, 2008)
- Major contributor to TCGA, PCGP, etc.
- Most comprehensively sequenced single patient tumor ever published (Griffith et al, 2015)
- Early proof-of-principle for cancer precision medicine (Griffith et al, 2016)
- Analysis and tools for first personalized cancer vaccine design in humans (Carreno et al, 2015)
- Many other widely used tools



Overview of lab's research (griffithlab.org)

Cancer genome analysis

- Breast cancer, Liver cancer, Lung cancer, Head and neck cancer, etc.
- Variant Interpretation
- Immunogenomics

Precision medicine for cancer

- Genomics Tumor Board
- <u>Case Reports</u>
- <u>Clinical Trials</u>
- Personalized Cancer Vaccines

Education projects

- <u>RNA-seq analysis and cloud computing (CBW, Toronto)</u>
- Advanced Sequencing Technologies and Applications (CSHL, New York)
- Genomic Data Visualization/Interpretation (Physalia Courses, Berlin)
- <u>Precision Medicine Bioinformatics</u> (PR Informatics, Glasgow)
- <u>High-Throughput Biology: From Sequence to Networks</u> (<u>CSHL</u> / <u>CBW</u>, New York)
- <u>Workshop on Genomics</u> (Evomics, Český Krumlov)
- Tool development

Where tools/resources do not exist we build them



www.dgidb.org

Search genes for known and potentially druggable interactions



https://github.com/griffithlab/pVAC-Seq Personalize vaccine design



www.docm.info

Filter against highly curated set of mutations known to cause cancer




https://github.com/griffithlab/GenVisR Create genomic visualizations



www.civicdb.org


Identify highly curated summaries of clinical interpretations for variants in cancer






https://github.com/griffithlab/regtools Identify regulatory variants

Whole genome, exome, transcriptome and other 'omic' sequencing allows us to detect and confirm many different variant types




SNVs, Indels, CNVs, SVs, fusions, LOH, expression changes, methylation changes, and more




7

Comprehensive and integrative analysis methods are needed



Personalized medicine requires personalized strategies





Experimental Hematology

Experimental Hematology 2016;44:603-613

Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia

Griffith et al. 2016


Kilannin Krysiak



Strategies to bring genomics information to bear for as many cancer patients as possible

- 1. Precision medicine targeting of driver mutations
- 2. Leveraging passenger variants
 - a. Tracking minimal residual disease
 - b. Identifying neoepitopes
 - Predicting response to immunotherapy
 - Developing personalized vaccines

Precision medicine targeting of driver mutations



1980s: Development of Targeted Therapies

> 2000: Human Genome Sequencing Project

2001: FDA Approval for Imatinib in BCR-ABL1 CML


2014: FDA Approval for BRCA Testing

2017: FDA Approval of Pembro for MSI tumors

BRAF -> V600E -> Melanoma -> Predictive -> Vemurafenib ERBB2 -> Amplification -> Breast -> Predictive -> Traztuzumab EGFR -> L858R -> Lung -> Predictive -> Erlotinib ALK -> Fusions -> Lung -> Predictive -> Crizotinib EWSR1-FLI1 -> Fusions -> Ewing Sarcoma -> Diagnostic DNAJB1-PRKACA -> Fusions -> flHCC -> Diagnostic VHL -> Loss of function mutations -> Kidney -> Predisposing ... an increasingly long tail of rare but clinically relevant variants

Erica Barnell


High-throughput sequencing has been largely automated allowing rapid identification of somatic and germline variants



Good BM, Ainscough BJ, McMichael JF, Su AI, Griffith OL. 2014. Genome Biology. 15(8):438.




Interpretation and visualization of genomic alterations remains the bottleneck for realizing precision medicine



Good BM, Ainscough BJ, McMichael JF, Su AI, Griffith OL. 2014. Genome Biology. 15(8):438.



We created CIViC to address this need - an open knowledgebase and curation system for clinical interpretation of variants in cancer




www.civicdb.org




Strategies to bring genomics information to bear for as many cancer patients as possible

- 1. Precision medicine targeting of driver mutations
- 2. Leveraging passenger variants
 - a. Tracking minimal residual disease
 - b. Identifying neoepitopes
 - Predicting response to immunotherapy
 - Developing personalized vaccines

Circulating tumor DNA (ctDNA) could allow generalized tracking in any cancer type



ctDNA tracking in triple negative breast cancer






Strategies to bring genomics information to bear for as many cancer patients as possible

1. Precision medicine targeting of driver mutations

2. Leveraging passenger variants

- a. Tracking minimal residual disease
- b. Identifying neoepitopes
 - Predicting response to immunotherapy
 - Developing personalized vaccines


Invoking an adaptive immune response against the tumor (focus on CD8+ T cells)




Neoepitope characterization workflow

Jasreet Hundal & Katie Campbell

Shirley X. Liu, Elaine R. Mardis. Applications of Immunogenomics to Cancer. Cell Press. 2017.



T cell mediated cell death




Singh and Gulley, 2014

Personalized cancer vaccine trials


- Kidney Cancer (n = 15 patients)
 - PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma (<u>NCT03598816</u>). Collaboration with MedImmune.
- Lung Cancer (n = 15 patients)
 - A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer (NCT03380871). Collaboration with Neon Therapeutics and Merck.
- Glioblastoma (n = 30 patients)
 - Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (<u>NCT03422094</u>)
- Breast Cancer (n = 54 patients)
 - Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (<u>NCT03199040</u>). Collaboration with MedImmune.
 - Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy (NCT02348320)
- Follicular Lymphoma (n = 20 patients)
 - Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma (<u>NCT03121677</u>). Collaboration with Bristol-Myers Squibb.
- Prostate Cancer (n = 20 patients)
 - Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer (NCT03532217). Collaboration with Bristol-Myers Squibb.
- Pancreatic Cancer (n = 15 patients)
 - Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy (<u>NCT03122106</u>).
- Melanoma (n = 12 patients)
 - Dendritic Cell Vaccination in Patients With Advanced Melanoma (<u>NCT03092453</u>). Collaboration with UPenn/Parker ICI.

Genomic data visualization and interpretation

Genomics research has exploded with the rapid advances in DNA sequencing technologies



Whole genome, exome and transcriptome sequencing allows us to detect and confirm many different variant types



Why do we create visualizations of genomic data?

- Data exploration and interpretation of results
 - QC analysis
 - Understanding whether/how an experiment worked
 - Discovery
- Communication
 - Slides for presentations
 - e.g. Keynote, Powerpoint, etc.
 - Figures for publications
 - e.g. PDFs, PNGs, etc.
 - Illustrator, Gimp, Inkscape, etc.
 - R and R Studio

Genome browsers




Genome browsers - Ensembl

CENSEMBI BLAST/BLAT BioMart Tools Downloads Help & Documentation Blog Mirrors		
Search: All species of for		
Browse a Genome Ensembl is a genome browser for vertebrate genomes that supports research in comparative genomics, evolution, sequence variation and transcriptional regulation. Ensembl annotate genes, computes multiple alignments, predicts regulatory function and collects disease data. Ensembl tools include BLAST, BLAT, BioMart and the Variant Effect Predictor (VEP) for all supported species. Favourite genomes	Find a Data Display	
Human Mouse GRCh08.p10 GRCm38.p5 Zebrafish Edit fexourities	Variant Effect Predictor	Gene expression in different tissues
All genomes Select a species View full list of all Ensembl species	Retrieve gene sequence	Compare genes across species

Genome browsers - UCSC



Genome browsers - IGV




Fundamentals of data visualization



Fundamentals of data visualization


- Where to learn more about the art and science of visualization:
 - Collection of 40 Nature Methods articles on data visualization: <u>"Points of View" Articles</u>
 - Visual design principles lecture

Which series is more effective (top or bottom)?




Martin Krzywinski

Which series is more effective (top or bottom)?





34

Which is more effective (left or right?)



Which is more effective (left or right?)





Excellent organization and consistency. Vertical lines cue continuity. Good use of color.


Samollow, P.B., The opossum genome: insights and opportunities from an alternative mammal. Genome Res, 2008. 18(8): p. 1199-215. Chartjunk plentiful. Screaming ornamental and redundant elements. Text inconsistent and illegible.

Gentles, A.J., et al., Evolutionary dynamics of transposable elements in the short-tailed opossum Monodelphis domestica. Genome Res, 2007. 17(7): p. 992-1004.

Martin Krzywinski




Which is more effective (left or right?)



Non-small-cell lung cancer	1,563	15.1	
Breast carcinoma	1,237	11.9	
Colorectal cancer	978	9,4	The second se
Prostate cancer	623	6.0	
Glioma	512	4.9	
Pancreatic cancer	490	4.7	
Soft-tissue sarcoma	438	4.2	
Bladder cancer	408	3.9	
Melanoma	350	3,4	
Renal cell carcinoma	322	3.1	
Esophagogastric carcinoma	317	3.1	
Germ cell turnor	268	2.6	
Biliary cancer	242	2.3	
Thyroid cancer	226	2.2	
Ovarian cancer	217	2.1	
Endometrial cancer	211	2.0	
Head and neck carcinoma	179	1.7	
Cancer of unknown primary	160	1.5	
Non-Hodgkin lymphoma	159	1.5	
Skin cancer, non-melanoma	144	1,4	
Gastrointestinal stromal tumor	126	1.2	
Mesothelioma	106	1.0	
Hepatocellular carcinoma	105	1.0	
Salivary carcinoma	104	1.0	
Uterine sarcoma	91	0.9	
Small-cell lung cancer	88	0.8	
Embroyonal tumor	76	0.7	
Appendiceal cancer	70	0.7	
strointestinal neuroendocrine tumor	53	0.5	
Cervical cancer	47	0.5	
Osteosarcoma	42	0.4	
Ewing sarcoma	37	0.4	
Chondrosarcoma	36	0.3	
Small-bowel cancer	35	0.3	
Anal cancer	32	0.3	
Meningothelial tumor	32	0.3	
Adrenocortical carcinoma	26	0.3	
Ampullary carcinoma	25	0,2	
Histiocytosis	20	0.2	
Thymic tumor	18	0.2	
Sex cord stromal tumor	18	0.2	
Ependymomal tumor	16	0.2	
Nerve sheath tumor	15	0.1	
Chordoma	14	0.1	
Breast sa/coma	12	0.1	
Gestational trophoblastic disease	11	0.1	
Other	60	0.6	CHARLEN IN THE POLY IN THE SECOND
			50% 100%




When to use a pie chart



Martin Krzywinski

When to <u>not</u> use a pie chart



- Hard to judge proportions


Ahmet Zehir et al. (2017) Nature Medicine doi:10.1038/nm.4333

- Poor use of color
- Hard to read labels
- Over 1/2 of the categories had to broken out of the pie chart

Martin Krzywinski



Same data with a redesigned approach



Martin Krzywinski

40

Selected articles on fundamentals of data viz

- Visualizing samples with box plots
- <u>Circos plots</u>
- When to use (and not use) pie charts
- Resources for choosing colors
 - http://colorbrewer2.org/
 - http://mkweb.bcgsc.ca/color/
 - Understanding and using Color Palettes
 - <u>Color palettes for color blindness</u>
 - Names for >9000 colors
 - Including 40 beer colors
- Credit to Martin Krzywinski for his extensive work in this area and many of the above resources



Best practices in visualization

Best practices from this workshop

- *Always* label axes
- Consider readability of font size
- Avoid vertical or angled text if possible
- Avoid unnecessary use of color, point shapes, etc.
- Chose colors wisely
- If individual data points are being plotted and have started to really pile up on top of each other consider using a density function
- Always be transparent about what data manipulation is taking place (e.g. log scale, filtering of outliers, etc.)

Best practices from the experts


Ten Simple Rules for Better Figures (Rougier et al. 2014):

Scientific visualizations should act as a "a graphical interface between people and data". Try to follow these rules.


- 1. Know Your Audience
- 2. Identify Your Message
- 3. Adapt the Figure to the Support Medium
- 4. Captions Are Not Optional
- 5. Do Not Trust the Defaults
- 6. Use Color Effectively
- 7. Do Not Mislead the Reader
- 8. Avoid "Chartjunk"
- 9. Message Trumps Beauty
- 10. Get the Right Tool

Example visualizations using R

Histogram and scatterplot to define cell populations




Clustering to define to distinct cell populations




47


Using a "cell map" to represent the variant clusters in 100 hypothetical cells of a tissue



A 'fish' plot is used to represent sub-clones lost and gained over time




Visualizing copy number variation



KRAS amplification in a metastatic breast cancer

A 'waterfall' plot is one way to visualize the pattern of variant recurrence in a cohort of samples




Sample (n=405)


https://github.com/griffithlab/GenVisR



Heatmaps are a common way to simultaneously visualize multiple features of a dataset



GenVisR was created to help others make common genomic visualizations



53

Acknowledgements: Griffith Lab group members

OSCC

Katie

Campbell

pVAC-

seq/CIViC



Malachi Griffith




Arpad Danos





Josh **McMichael**



Obi Griffith





Yang-Yang Feng







Zachary

Skidmore

Cody Ramirez



DoCM

CIViC

Benjamin

Ainscough

Lymphoma

Felicia

Gomez

genVisR



Erica Barnell

pVAC-seq



Jasreet Hundal

CIViC/Komen



Nick Spies



Susanna

Kiwala


Lee Trani



CIViC



Kaitlin Clark





Kilanin **Krysiak**





Alex Wagner

CIViC/DGIdb





Adam

Coffman

CIViC

Lynzey

Kujan

Director





Kelsv Cotto

HCC



Jason Kunisaki



Jason Walker



HCC/SCLC

Acknowledgements: McDonnell Genome Institute

McDonnell Genome Institute @ Washington University School of Medicine

We are The Genome Institute. Scott Abbott, Travis E. Abbott, Derek C. Albracht, Mark A. Ames, Lucinda L. Antonacci-Fulton, Elizabeth L. Appelbaum, Kelly R. Becker, Michael C. Becker, Edward A. Belter Jr., Paul M. Bender, Angela K. Bentlage, Veena Bhonagiri, Tamberlyn Bieri, Thomas D. Biewald, Andrew P. Bohannon, Kirk A. Brege, Rose L. Brockhouse, Anthony M. Brummett, Mark M. Burnett, Christopher R. Cabanski, Theresa A. Caesar, Matthew B. Callaway, Francine R. Camacho, Edgar A, Campbell, Darren Casimere, Wan-Ching Chan, Lei Chen, Mari Jo Clark, Adam C. Colfman, Lisa L. Cook, Matthew Cordes, Laura P. Courtney, Amy K. D'Albora, John S. Dalbora, Indraniel Das, Sara E. Decarlo, Nathan D. Dees, Kimberley D. Delehaunty, Brandon J. Delgado, Anthony M. DeLuca, Tracie L DeLuca, Ryan T. Demeter, Ricardo A. DeMoya, Brian R. Derickson, Li Ding, Kara R. Dix, Gregory P. Dooling, Felyu Du, James M. Eldred, Efrem Exum, Jason M. Falcone, Candace N, Farmer, Ian T, Ferguson, Grace M, Freeman, Catrina C, Fronick, William L, Fronick, Bradley T, Fulton, Robert S. Fulton, Kristi N. Futhey, Xin Gao, Barbara Gillam, Chakravarthy Girda, Jennifer Godfrey, Jenna Christine Goeckner, Laura Jane Gottschalk, Susan D. Grasso, Malachi Griffith, Obi Griffith, Jeanne M. Grigsby, David S. Gudermuth, Priscilla Hale, Terri M. Hall, Kevin V. Haub, Amy E. Hawkins, Todd G. Hepler, Brandi N. Herter, Jennifer S. Hodges, Kimberly Hughes, Jasreet Hundal, Stephanie M. Jackson, Rodney L. Jones, Wendall B. Jones, Krishna L. Kanchi, Cyriac Kandoth, Kimberly Diane Keen, Kyung H. Kim, Michael J. Kiwala, Daniel Koboldt, Sara Kohlberg, Colin L. Kremitzki, Milinn R. Kremitzki, Sheila R. Lakanen, David E. Larson, Sai Harn Lek, Shawn M. Leonard, Shin F. Leong, Andrew D. Levy, Shannon M. Lewis, Timothy J. Ley, Ling Lin, Tina A. Lindsay, Charles Lu, Kaelyn A. Lundry, Amy L. Ly, Sandra K. MacMil-Ian, Vincent J. Magrini, Lenon G. Maguire, Christopher A Maher, Jennifer Maher, Rondy Janjak Malik, Elaine R. Mardis, Christopher M. Markovic, John C. Martin, Judith M. Mc Cart, Suzanne E. McGaugh, Sean D McGrath, Michael D. McLellan Joshua F. McMichael, Samantha N. McNulty, Brian Meininger, Karyn N. Meltz Steinberg, Kathie A. Mihindukulasuriya, Lenka Mikalova, Christopher A. Miller, Walter Miller, Patrick J. Minx, Makedonka Mitreva, Deborah S. Moeller, Michael J. Montague, Thomas B. Mooney, Andrew Z. Morrison, David L. Morton, Jennifer B. Murphy, Pamela A. Nangle, William E. Nash, Maze Bi Ndukum Ndonwi, Joanne O. Nelson, Nham Nhan, Beifang Niu, Nathaniel G. Nutter, Benjamin J. Oberkfell, David J O'Brien, Kerri R. Ochoa, Gretchen A. O'Donnell, Michelle D. O'Laughlin, Philip Jeffrey Ozersky, Stephanie J. Parrish, Josh Peck, Kymberlie A. Pepin, Stephanie K. Pleasant, Craig S. Pohl, Eric Ponce, Allison Ann Regier, Amy D. Reily, Gaia A. Remerowski, Natalia Rivera, Susan M. Rock, Ronald E. Rodriguez-Santiago, Irina R. Ronko, Bruce A. Rosa, Kelsi M. Rotter, Ryan J. Rupp, Gabriel Eugene Sanderson, Amy P. Sansone, Kyriena L. Schatzkamer, Debra E. Scheer, Heather K. Schmidt, Michael T. Schmidt, Zachary L. Schools, William E. Schroeder, N'Desha T'vorle Scott, Harry E. Senaldi, Cherilynn R. Shadding, Nicholas T. Sheehan, Dong Shen, Susanna Siebert, Jessica M. Silva-Fisher, Julie T. Smith, Scott M. Smith, Erica J. Sodergren Weinstock, Steven S. Spargur, John G. Spieth, Gary P. Stiehr, Dennis B. Striegel, Cynthia L. Strong, Dawn K. Sutter, Kenneth B. Swanson, Yat T. Tang, Andrea R. Taylor, Thynn K. Thane, Brenda A Theising, Audra S Thomas-Monti, Brianne M. Thomeczek, Valerie L. Thompson, Chad M. Tomlinson, Lee M. Trani, Nikki L. Trapp, John L. Trevaskis III, Evanne Trevaskis, Richard Trippeer, Rusudan B, Turabelidze, Rahul Tvagi, Joelle M, Veizer, Tammi L, Vickery, Jason E. Waligorski, Jason R. Walker, Latricia E. Wallace, John W. Wallis, Qi Wang, Wesley C. Warren, Brian H., Watts, James V. Weible, Matthew R. Weil, George M. Weinstock, Michael C. Wendl, Richard K. Wilson, Roxanne M. Wilson, Ave M. Wollam, Dee Wu, Kristine M. Wylie, Todd N. Wylie, Kai Ye, Xu Zhang, Yanjiao Zhou

Susan Dutcher Tim Ley

Bob Fulton Lucinda Fulton Ira Hall Dave Larson Chris Maher Lukas Wartman

Matt Callaway Chris Miller Jason Walker

Introduction to GenViz course site

www.genviz.org

